Search papers, labs, and topics across Lattice.
This study introduces DeepBD, a novel workflow that leverages large language models (LLMs) and a pretrained evidence engine to prioritize genetic variants associated with birth defects. By integrating diverse sources of evidence, including population genetics and phenotype ontologies, DeepBD effectively ranks candidate variants, achieving superior performance compared to existing tools like Exomiser and DeepRare on a substantial internal dataset of 18,622 cases. The results demonstrate that the combination of structured rule evidence and specialist modules enhances diagnostic accuracy, paving the way for improved clinical decision-making in genetic diagnostics.
DeepBD outperforms traditional variant prioritization tools by integrating LLMs and specialized evidence modules, achieving a Recall@10 of 92.9% on a large cohort of genetic cases.
Birth defects are a major cause of fetal loss, neonatal morbidity and long-term disability. In the subset with suspected genetic etiologies, exome and genome sequencing have moved many cases from variant detection to post-sequencing interpretation: clinicians must rank patient-specific candidate variants under incomplete fetal or infant phenotypes and heterogeneous evidence from population genetics, variant-effect prediction, gene-disease validity, phenotype ontologies, cellular and pathway context, protein structure and clinical literature. We present DeepBD, a grounded agentic workflow for variant prioritization and diagnostic interpretation of genetic birth defects. DeepBD organizes the workflow into LLM-assisted case structuring, a pretrained evidence engine, specialist evidence modules and a grounded diagnostic review layer. The evidence engine learns patient-specific variant scores from structured rule evidence, sequence and variant-effect representations and phenotype-conditioned biological context, whereas specialist modules and the agentic layer provide tool-based refinement, candidate-pool review and diagnosis-oriented synthesis from ranked candidates. Developed using an in-house fetal and infant cohort comprising 18,622 cases, DeepBD achieved Recall@1/3/5/10 of 0.658/0.882/0.912/0.929 on an internal held-out solved-case benchmark, outperforming standalone Exomiser, DeepRare and prompted LLM reranking baselines evaluated on Exomiser-derived top-20 candidate variants. Ablation and overlap analyses show that rule evidence, mechanistic context, and specialist refinement provide complementary signals. These findings support a grounded agentic workflow that separates evidence integration, tool-based refinement, and LLM-assisted diagnostic review for retrospective variant prioritization in genetic birth defects.
